医薬品とバイオテクノロジーにおける共同開発取引：2016年～2025年

医薬品とバイオテクノロジーにおける共同開発案件は、企業が共同開発案件に参入する方法と理由について詳細な理解と分析を提供します。

当レポートでは、2016年から2025年までの共同開発案件の詳細を提供しています。当事者間で発表された共同開発取引の支払い条件へのアクセスを提供します。このデータは、支払い条件やその他の取引条件に関する有用な洞察を提供します。

パートナー候補が交渉した取引条件の柔軟性を理解することで、条件交渉中に何を期待できるかという点で、交渉プロセスに対する重要な洞察が得られます。多くの中小企業は支払い条項の詳細を求めるだろうが、支払の発動や権利の移転の方法については、細部にこそ悪魔が潜んでいます。

当レポートでは、2016年以降に発表された共同開発案件について、Current Agreementsの案件・提携データベースに記録されているものを包括的にリストアップし、入手可能な場合には財務条件も記載しているほか、企業とそのパートナーが証券取引委員会に提出した実際の共同開発取引文書のオンラインコピーへのリンクも掲載しています。

当レポートの最初の章では、共同開発の取引と事業活動について解説しています。

第1章では、当レポートのイントロダクションを提供し、第2章では、共同開発の動向の概要と分析、および取引タイプのメリットについての議論を提供しています。

第3章では、共同開発案件の構造について概観しています。

第4章では、2016年以降の代表的な共同開発案件のレビューを行う。案件はヘッドライン金額別に掲載しています。案件がSECで公表された契約書を持っている場合、リンクはCurrent Agreements deals and alliancesデータベースを介して契約書へのオンラインアクセスを提供します。

第5章では、最も活発な共同開発取引メーカー企業上位25社の包括的なリストを提供しています。各取引タイトルは、Current Agreements deals and alliancesのデータベースを通じて、取引レコード全文のオンラインバージョンにリンクしており、利用可能な場合には実際の契約文書にもリンクしているため、各取引レコードにオンデマンドで簡単にアクセスすることができます。

第6章では、契約文書が入手可能な場合、2016年以降に締結・発表された共同開発案件を企業A-Z、治療法、技術、業種別に整理し、包括的かつ詳細にレビューしています。契約文書では、共同開発案件に関して当事者間で合意された実際の取引条件に関する詳細な洞察を提供します。

案件ディレクトリには、2016年以降に発表されたすべての共同開発案件の包括的なリストが含まれています。各リストは、企業A-Z、治療領域、技術タイプ別に取引ディレクトリーとして構成されています。各取引タイトルは、ハイパーリンクを通じて、利用可能な場合には実際の契約文書を含む取引レコードのオンライン版にリンクしています。

当レポートには、2016年以降の共同開発取引メーキングの動向と活動を示す多数の図表も含まれています。

結論として、当レポートは、共同開発アライアンスについて、将来の取引メーカーが知る必要のあるすべてを提供します。

目次

エグゼクティブサマリー

第1章 イントロダクション

第2章 共同開発取引の動向

• イントロダクション
• 共同開発取引の定義
• 2016年以降の共同開発取引の動向
  • 共同開発取引の年別推移、2016年～2025年
  • 共同開発取引、2016年～2025年、開発段階別
  • 共同開発取引、2016年～2025年、業界別
  • 共同開発取引、2016年～2025年、治療領域別
  • 共同開発取引、2016年～2025年、技術タイプ別
  • 最も活発な企業別共同開発取引、2016年～2025年
• 共同開発提携契約を締結する理由
• 共同開発取引の将来

第3章 共同開発取引構造の概要

• イントロダクション
• 共同開発取引の構造

第4章 共同開発取引の主導

• イントロダクション
• 主要な共同開発取引、金額別

第5章 -最も活発な共同開発取引メーカー主要25社

• イントロダクション
• 最も活発な共同開発取引メーカー主要25社

第6章 -契約ディレクトリを含む共同開発取引

• イントロダクション
• 2016年から2025年までの契約別共同開発取引
• 取引ディレクトリ
• 取引ディレクトリ- 企業別共同開発取引（AZ）
• 取引ディレクトリ- 共同開発取引、治療領域別
• 取引ディレクトリ- 共同開発取引、技術タイプ別
• 調査会社について
• 現在の提携
• 現在の契約
• Current Partneringからの最近のレポートタイトル

Co-development Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-development deals.

Fully revised and updated, the report provides details of co-development deals from 2016 to 2025.

The report provides access to co-development deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of co-development deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of co-development dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-development as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of co-development deals.

Chapter 4 provides a review of the leading co-development deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active co-development dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 6 provides a comprehensive and detailed review of co-development deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-development deal.

The deal directory includes a comprehensive listing of all co-development deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in co-development dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-development alliances.

Key benefits

Co-development Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse co-development deals
• Benchmark analysis - identify market value of transactions
• Financials terms
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Co-development Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading biopharma companies worldwide.

Co-development Deals in Pharmaceuticals and Biotechnology includes:

• Trends in co-development dealmaking in the biopharma industry
• Overview of co-development deal structure
• Directory of co-development deal records covering pharmaceutical and biotechnology
• The leading co-development deals by value
• Most active co-development dealmakers
• The leading co-development partnering resources

In Co-development Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Co-development Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for co-development deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the rights granted or optioned?
• What rights are granted by the agreement?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are intellectual property rights handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in co-development dealmaking

• 2.1. Introduction
• 2.2. Definition of co-development deal
• 2.3. Trends in co-development deals since 2016
  • 2.3.1. Co-development dealmaking by year, 2016-2025
  • 2.3.2. Co-development dealmaking by phase of development, 2016-2025
  • 2.3.3. Co-development dealmaking by industry sector, 2016-2025
  • 2.3.4. Co-development dealmaking by therapy area, 2016-2025
  • 2.3.5. Co-development dealmaking by technology type, 2016-2025
  • 2.3.6. Co-development dealmaking by most active company, 2016-2025
• 2.4. Reasons for entering into co-development partnering deals
• 2.5. The future of co-development deals

Chapter 3 - Overview of co-development deal structure

• 3.1. Introduction
• 3.2. Co-development agreement structure

Chapter 4 - Leading co-development deals

• 4.1. Introduction
• 4.2. Top co-development deals by value

Chapter 5 - Top 25 most active co-development dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active co-development dealmakers

Chapter 6 - Co-development deals including contracts directory

• 6.1. Introduction
• 6.2. Co-development deals with contracts 2016-2025
• Deal directory
• Deal directory - co-development dealmaking by companies A-Z
• Deal directory - co-development dealmaking by therapy area
• Deal directory - co-development dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of co-development deal
• Figure 2: Trends in co-development deal announcements, 2016-2025
• Figure 3: Co-development deals signed at each phase of development, 2016-2025
• Figure 4: Co-development deals by industry sector, 2016-2025
• Figure 5: Co-development deals by therapy area, 2016-2025
• Figure 6: Co-development deals by technology type, 2016-2025
• Figure 7: Top 25 most active co-development dealmakers, 2016-2025
• Figure 8: Top co-development deals by value, 2016-2025
• Figure 9: Most active co-development dealmakers, 2016-2025